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way to analyze our data would have been to pool all the data
obtained with the two different LMWHs; major chemical, bio-
logical and clinical differences exist between these LMWHs, and
there has been much debate on this issue. We believe that pooling
these data would have generated many more letters to the editor!
There are few biological markers of prognosis in unstable
angina. Our recent studies have focused attention on vWf as a new
marker of potential interest in acute coronary syndromes. It
appeared consistently as a predictive factor of outcome, and we
believe it deserves attention and further evaluation in large studies.
Our most recent publication demonstrated that the new antico-
agulants tested in unstable angina behave better than UH with
regards to vWf release. We agree it should also be confirmed.
Step-by-step we are progressing in the understanding of the role of
vWf in the prognosis of unstable angina, and the time has come for
head-to-head comparisons between the new anticoagulant treat-
ments. In that regard, the ARMADA study has now been
completed and we will share the data very soon. I am sure that Dr.
Ho¨dl will appreciate the results.
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Enoxaparin for Acute Coronary Syndromes?
Goodman et al. (1) conclude that enoxaparin is a more effective
antithrombotic treatment than unfractionated heparin (UFH) for
the prevention of rebound ischemia in patients with unstable
angina or non-Q-wave myocardial infarction. We suggest an
alternative conclusion.
Enoxaparin’s plasma half-life is two to four times longer as
compared to UFH after subcutaneous administration (2), even
more when compared to UFH given intravenously, as in the
Goodman et al. study. Activity against factor Xa and thrombin
disappears only after more than 16 h (3), following moderate doses
of enoxaparin. With high doses, as used in the ESSENCE study
(1), enoxaparin’s plasma half-life is substantially longer (4).
Therefore, after stopping study drugs in the ESSENCE study,
enoxaparin’s antithrombotic effect very likely lasted much longer
than that of UFH. After stopping UFH, ischemic events during
the 48-h monitoring period were twice as frequent as after
stopping enoxaparin (45% vs. 26%), whereas there was no differ-
ence while on active treatment (25%)—compatible with an anti-
thrombotic effect lasting about one day longer after enoxaparin. In
addition, enoxaparin’s antithrombotic effect wanes much more
slowly as compared to IV UFH. This may have added benefit by
attenuating a heparin rebound effect.
It remains to be convincingly shown whether enoxaparin or
other low-molecular-weight heparins exert superior antithrom-
botic effects as compared to UFH. Superior clinical benefit might
be explained by pharmacokinetic differences only. For patients
with acute coronary syndromes, extending the duration and slower
weaning (5) of IV UFH may well be better and cheaper.
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REPLY
Pechlaner et al. suggest that our findings (1) of less rebound
ischemia with enoxaparin as compared to unfractionated heparin
(UFH) are simply due to the longer half-life of enoxaparin.
However, the ischemic episodes (average number and duration)
identified during continuous electrocardiographic monitoring were
statistically significantly lower in the enoxaparin as compared to
the UFH group not only during the first 12 h after drug
discontinuation but also during the .12 to 24-h and even the .36
to 48-h time intervals. This suggests that the benefit seen with
enoxaparin is not simply due to prolonged half-life and greater
anti-Xa:IIa activity that “wanes” more slowly than UFH. Indeed,
there is growing evidence supporting additional mechanisms of
benefit of enoxaparin over UFH beyond the differences in phar-
macokinetics; for example, the significant blunting of the rise of
von Willebrand factor with enoxaparin in the first 48 h of
treatment (2).
As we noted, our substudy (1) was stopped at the time of overall
trial completion but prior to enrollment of an adequately powered
sample size to confidently address the initial 48-h period of active
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treatment. Nonetheless, among the subgroup of patients who
underwent monitoring during both the initial treatment and study
drug discontinuation periods (n 5 163), ischemia was less fre-
quently observed during both monitoring periods in the enoxaparin
group (18.4% vs. 32.2%, p 5 0.045 and 25% vs. 46%, p 5 0.005,
respectively). Further, the time to first ischemic episode was
significantly earlier among UFH-treated patients, consistent with
a superior early antithrombotic effect of enoxaparin and a reduction
in the composite clinical end point of death, myocardial infarction
(MI), and need for urgent revascularization (3).
Therefore, we believe that enoxaparin has been shown to be
superior to UFH based upon the consistent and statistically
significant reductions in the composite and double (death/MI) end
points in ESSENCE and TIMI 11B (4). In contrast, “extending
the duration and slower weaning” of UFH is an unproven method
of administration, and, in fact, the cost-savings realized with
enoxaparin ultimately make it the less expensive option (5).
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Failure of Right Ventricular
Recovery of Fallot Patients After
Pulmonary Valve Replacement:
Delay of Reoperation or Surgical Technique?
We read with great interest and surprise the article published by
Therrien et al. in the November issue of the Journal (1). These
results are extremely disappointing. All the physicians familiar
with the treatment of patients with repaired tetralogy of Fallot
share the idea that one should not wait too long before implanting
a valve in the right ventricular outflow tract of patients presenting
with dilated right ventricle. Extremely dilated right ventricles
might not benefit from valvulation as much as moderately dilated
ones. However, it is extremely surprising that all patients operated
on in a major center like Toronto showed neither clinical improve-
ment nor regression of ventricular volumes after reoperation.
Although their patients were operated on quite late, we wonder
whether their unexpectedly bad results might not be related to
another reason than the delay for reoperation. The Toronto team
has the peculiarity of implanting bioprosthetic material in the right
ventricular outflow tract of these patients. Almost all patients
received a stented bioprosthesis varying in size between 25 and
33 mm in diameter. It is noteworthy that true diameters of the
outer rings are even larger than these measurements. The only way
to implant these rather bulky bioprostheses at the level of the
pulmonary annulus is to cover them with a patch extending from
the main pulmonary artery to the infundibulum of the right
ventricle. The immediate effect of this patching is to further
increase the size of the right ventricular cavity, which may at least
partly explain the fact that no decrease was observed in end-systolic
and end-diastolic volumes of these patients after reoperation. We
have recently shown that pulmonary insufficiency might not be the
leading factor causing right ventricular dilation after repair of
tetralogy of Fallot, and we suspect that the contractile function of
the pulmonary infundibulum may play a role in the preservation of
right ventricular function (2). Adding a patch to this already
weakened area might further contribute to the deterioration of this
function.
Like others, we believe that homografts are the ideal valve
substitute for the right ventricular outflow tract because they offer
a better effective orifice area, and they do not necessitate a patch
enlargement. Although 40% of the patients presented in this series
had an aneurysm resection, it is not clear whether the researchers
believe that they effectively reduced right ventricular size at the
time of the procedure.
In conclusion, we wonder whether the extremely poor results
presented by Therrien et al. (1) might not be at least partially
explained by their surgical technique rather than by the delay in the
reoperation. The insertion of a patch in the already dilated area of
the pulmonary infundibulum might further impede right ventric-
ular function and as such increase rather than decrease right
ventricular volumes.
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